Modified HCV Genomic RNA for Autonomous Replication and Particle Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for replicating and purifying hepatitis C virus (HCV) in cultured cell systems are limited, particularly for various genotypes, making it difficult to analyze therapeutic effects and produce vaccines, as existing systems are inefficient and can't stably produce HCV virus particles with different genotypes.
Innovation Solution
Modified HCV genomic RNA is created by combining genomic RNA of an autonomously replicable JFH1 strain with non-replicable strains, allowing for autonomous replication in cultured cells, and HCV particles are purified using chromatography and density gradient centrifugation to produce infectious particles for therapeutic and vaccine applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If HCV subgenomic RNA replicon is produced by substituting structural protein with neomycin resistance gene and EMCV-IRES, then autonomous replication in cultured cells is achieved, but the system can only evaluate RNA replication during virus growth and cannot evaluate virus particle formation, release, and infection processes
Solution Approach 1:
The invention divides the HCV genome into functional segments: the replicon system (for RNA replication evaluation) and the structural protein-coding region (for virus particle formation and infection evaluation). This segmentation allows the replicon to autonomously replicate while retaining the ability to produce infectious virus particles when combined with appropriate structural proteins, thus enabling both replication analysis and virus lifecycle evaluation.
Solution Approach 2:
The invention uses the HCV replicon as an intermediary system that can be independently cultured and then used to produce infectious virus particles. The replicon serves as a mediator between in vitro RNA replication studies and in vivo virus particle formation, allowing researchers to first establish replication competence and then generate virus particles for infection studies without requiring direct animal experimentation.
2Reliability
If HCV intracellular RNA replication systems are produced for limited genotypes, then replication analysis is possible for those specific strains, but it becomes extremely difficult to analyze therapeutic effects across different HCV genotypes
Solution Approach 1:
The invention creates a universal HCV replicon system that can support RNA replication for multiple HCV genotypes. By designing the replicon with conserved functional elements that are compatible with different genotype-specific NS3 proteases and other viral proteins, the system enables reliable replication analysis across genotype 1a, 1b, 2a, 2b, 3a, and 3b, allowing broad-spectrum therapeutic evaluation without requiring separate replication systems for each genotype.
Solution Approach 2:
The invention modifies the replicon system's parameters (such as promoter sequences, IRES elements, and protein coding regions) to accommodate variations across different HCV genotypes. These parameter adjustments allow the replicon to maintain autonomous replication capability while being adaptable to genotype-specific viral proteins, thereby enabling cross-genotype therapeutic effect analysis with a single versatile system.
3Adaptability or versatility
If animal experimental systems are used to analyze HCV virus particle formation, release, and infection processes, then comprehensive virus lifecycle evaluation is possible, but the operations become complicated and extremely difficult to conduct
Solution Approach 1:
The invention creates an in vitro copy of the HCV virus particle formation and infection process using cultured cells and the HCV replicon system. Instead of requiring complex in vivo animal models, the system reproduces the essential virus lifecycle events (particle assembly, release, and infection) in a controlled cell culture environment, maintaining evaluation capability while dramatically simplifying the experimental system and eliminating the need for animal experimentation.
4Quantity of substance
If existing HCV purification methods are used, then some HCV particles can be obtained, but the purification efficiency is insufficient for industrial use and high-purity HCV particles cannot be achieved
Solution Approach 1:
The invention performs preliminary concentration of HCV particles from culture supernatant before applying chromatography purification steps. This preliminary concentration step increases the HCV particle density in the starting material, thereby improving the overall purification efficiency and enabling the subsequent chromatography steps to achieve high-purity product suitable for industrial applications, rather than attempting to purify dilute virus particles directly.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the stable production of HCV virus particles with various genotypes in a cultured cell system, facilitating the analysis of infection processes and the development of therapeutic agents and vaccines, while improving purification efficiency to achieve high-purity HCV particles for industrial use.
Implementation Method 1
the RNA replicon autonomously replicates in Huh7 cells
Implementation Method 2
HCV particles are purified using chromatography and density gradient centrifugation
Implementation Method 3
HCV particles are purified using chromatography and density gradient centrifugation
Data Source
AI summary
The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1.